Tribes against malaria increase Coronavirus mortality

The antimalarial medicine that is being promoted as a possible cure for COVID-19 has not been effective against the disease, but even increasing mortality has shown an analysis of its use in American hospitals. According to AFP and AP, the study found there were more deaths among patients with COVID- 19, who received [...]
The antimalarial medicine that is being promoted as a possible cure for COVID-19 has not been effective against the disease, but even increasing mortality has shown an analysis of its use in American hospitals.
According to AFP and AP, the study found there were more deaths among patients with COVID- 19, who received hydrochlorine than among those who receive standard care.
According to the AP, 28 percent of patients who received hydrochlorines carefully died, and 11 percent died from those who received only regular treatment.
Of those who receive hydroxicolin and azitromycin, about 22 percent died, but the difference between this group and the common care group is not considered large enough to exclude other factors that may have contributed to survival.
The use of hydrocycle also did not affect the need for respiratory use.
The AFP writes that the experiment had some significant restrictions but raised doubts about the effectiveness of the drug that has more support for President Donald Trump and Fox News channel.
France's news agency adds it is difficult to generalise the results, as the population surveyed is very specific -- most patients were men, on average, 65 years old.
Researchers, according to the AP, also did not monitor the side effects, but noted an allusion that hydrochlororia can have a harmful effect on other organs.
The medicine has long been known to cause possible serious side effects, including changes in heart rate that could cause sudden death.
Previous research has confirmed that this drug is dangerous for heart patients. The AP reports that scientists in Brazil suspended part of a study of chloroquine, an older drug similar to hydrochlororina, at the beginning of the month, as heart problems occurred in a quarter of those who received stronger doses or two doses.












